$7.4 Bil­lion Set­tle­ment With Purdue Pharma in Opi­oid Epidemic

Translate to Spanish or other 102 languages!

exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
- Advertisement -

Texas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. 

Purdue, under the Sacklers’ leadership, invented, manufactured, and aggressively marketed opioid products for decades, fueling waves of addiction and overdose deaths across the country. The settlement ends the Sacklers’ control of Purdue and their ability to sell opioids in the United States. Further, it will deliver funding directly to communities across the country over the next 15 years to support opioid addiction treatment, prevention, and recovery programs. The $7.4 billion settlement in principle, the nation’s largest settlement to date with individuals responsible for contributing to the opioid crisis, comes after the United States Supreme Court overturned a prior multistate settlement with the Sacklers and Purdue in June 2024.

“For years, I have aggressively worked to hold Purdue Pharma and other corporations accountable for their roles in creating and exacerbating the deadly opioid crisis that harmed so many Americans,” said Attorney General Paxton. “While nothing can restore the damage done, this settlement will provide Texans valuable resources to help prevent more opioid abuse. It was an honor to help lead these negotiations and I will never stop ensuring that justice is secured for those affected.” 

- Advertisement -

Attorney General Paxton has been a national leader in holding companies accountable for their roles in the opioid crisis, securing over $3 billion in settlements with Johnson & JohnsonWalmartWalgreensCVS, and other companies. 

Joining Attorney General Paxton in securing the settlement in principle are the attorneys general of California, Colorado, Connecticut, Delaware, Florida, Illinois, Massachusetts, New York, Oregon, Pennsylvania, Tennessee, Vermont, Virginia, and West Virginia.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Hidalgo County Expands Free Narcan Access With Five Vending Machines

Hidalgo County has expanded public access to naloxone, commonly known by the brand name Narcan, through five vending machines that provide the potentially life-saving medication free.

OpEd: Prostate Cancer Awareness; A Conversation That Could Save your Life

“Talk to your doctor.” That’s a phrase you commonly hear when it comes to questions about your health. For men, it’s particularly important for prostate cancer screening. September is Prostate Cancer Awareness Month, a great time to learn more about this common cancer.

Children’s Suicide-Related Emergency Visits Spiked by 74% in U.S.

Emergency visits by children with suicide-related crises increased by 74%, according to a study representing over 5 million emergency department (ED) visits for mental health concerns by U.S. children from 2016 to 2022.

FDA Intervenes to Secure Supply of Critical Neonatal Nutrition Products

The U.S. Food and Drug Administration today announced it is taking action, consistent with the Trump administration’s commitment to protecting vulnerable patients and maintaining access to critical medical products, to help address a potential supply gap of neonatal starter parenteral nutrition (PN).
- Advertisement -